Targeted protein degradation (TPD) | BMG LABTECH

Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area. Amphista focuses on the development of novel TPD approaches. How do these targets differ from more traditional ‘druggable’ targets and what are the benefits of this approach? TPD approaches can completely remove pathogenic proteins, rather than just inhibiting their function, providing potential for more potent or broader pharmacology, improved...